What insurance policy changes affect CPT 96417?

There are 40 tracked policy changes affecting CPT 96417, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 96417?

Payers that have issued tracked updates for CPT 96417 include: Aetna.

How do I get notified when CPT 96417 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 96417. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 96417?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

96417 — An additional separate chemotherapy drug given through an IV line during the same treatment session.: Insurance Policy Changes

96417 Insurance Policy Changes

CPT 96417, in plain terms, covers An additional separate chemotherapy drug given through an IV line during the same treatment session. CPT 96417 is referenced in 40 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 96417 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Avelumab (Bavencio) (CPB 0916, reviewed 2026-10-14)

Aetna·Identified Oct 15, 2026

This is a medical policy review (CPB 0916) for Avelumab (Bavencio) from Aetna commercial plans that establishes coverage criteria for multiple cancer indications including Merkel cell carcinoma, renal cell carcinoma, urothelial carcinomas, gestational trophoblastic neoplasia, endometrial carcinoma, thymic carcinoma, extranodal NK/T-cell lymphoma, colorectal adenocarcinoma, and small bowel adenocarcinoma. The policy requires precertification for all uses and specifies that members with disease progression on prior PD-1 or PD-L1 inhibitor therapy are excluded. No specific effective date is stated in the source; the document shows a review date of 2026-10-14.

Nipocalimab-aahu (Imaavy) (CPB 1083, reviewed 2026-08-11)

Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro) (CPB 0995, reviewed 2026-08-05)

Belantamab Mafodotin-blmf (Blenrep) (CPB 0981, reviewed 2026-02-06)

Daunorubicin-Cytarabine Liposome (Vyxeos) (CPB 0921, reviewed 2026-06-12)

Azacitidine (CPB 0960, reviewed 2026-06-12)

Anifrolumab-fnia (Saphnelo) (CPB 0997, reviewed 2026-06-05)

Fam-trastuzumab Deruxtecan-nxki (Enhertu) (CPB 0966, reviewed 2026-05-15)

Ciltacabtagene Autoleucel (Carvykti) (CPB 1007, reviewed 2026-03-13)

Brexucabtagene Autoleucel (Tecartus) (CPB 0980, reviewed 2026-03-13)

Carfilzomib (Kyprolis) (CPB 0845, reviewed 2026-03-02)

Irinotecan Liposome Injection (Onivyde) (CPB 0902, reviewed 2026-02-24)

Dostarlimab-gxly (Jemperli) (CPB 0993, reviewed 2026-01-27)

Panitumumab (Vectibix) (CPB 0748, reviewed 2025-12-23)

Radium Ra 223 Dichloride (Xofigo) (CPB 0874, reviewed 2025-12-22)

Oxaliplatin (CPB 0683, reviewed 2025-12-05)

Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro) (CPB 0995, reviewed 2026-10-16)

Axicabtagene Ciloleucel (Yescarta) (CPB 0924, reviewed 2026-10-09)

Avelumab (Bavencio) (CPB 0916, reviewed 2026-10-14)

Tisagenlecleucel (Kymriah) (CPB 0920, reviewed 2026-09-11)

Loncastuximab Tesirine-lpyl (Zynlonta) (CPB 0994, reviewed 2026-09-15)

Gemcitabine (CPB 0958, reviewed 2026-07-17)

Belantamab Mafodotin-blmf (Blenrep) (CPB 0981, reviewed 2026-10-16)

Tagraxofusp-erzs (Elzonris) (CPB 0947, reviewed 2026-05-28)

Margetuximab-cmkb (Margenza) (CPB 0985, reviewed 2026-05-27)

ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) (CPB 0780, reviewed 2026-04-27)

Tebentafusp-tebn (Kimmtrak) (CPB 1005, reviewed 2026-04-09)

Spesolimab-sbzo (Spevigo) (CPB 1013, reviewed 2026-04-02)

Fosdenopterin (Nulibry) (CPB 0991, reviewed 2026-03-27)

Naxitamab-gqgk (Danyelza) (CPB 0984, reviewed 2026-01-13)

Ibalizumab-uiyk (Trogarzo) (CPB 0936, reviewed 2025-12-30)

Idecabtagene Vicleucel (Abecma) (CPB 0992, reviewed 2025-12-19)

Loncastuximab Tesirine-lpyl (Zynlonta) (CPB 0994, reviewed 2025-12-09)

Sutimlimab-jome (Enjaymo) (CPB 1006, reviewed 2025-12-03)

Pegaspargase (Oncaspar) (CPB 0959, reviewed 2025-12-03)

Caplacizumab-yhdp (Cablivi) (CPB 0949, reviewed 2025-12-03)

Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Rylaze) (CPB 0864, reviewed 2025-12-02)

Blinatumomab (Blincyto) (CPB 0891, reviewed 2025-10-30)

Ziv-Aflibercept (Zaltrap) (CPB 0842, reviewed 2025-12-09)

Mogamulizumab-kpkc (Poteligeo) (CPB 0940, reviewed 2026-04-28)

Temsirolimus (Torisel) (CPB 0873, reviewed 2026-10-08)